ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Core Viewpoint - ReShape Lifesciences has partially adjourned its Special Meeting of Stockholders to allow more time for soliciting proxies regarding the Asset Sale Proposal and Charter Amendment Proposal, which are essential for the completion of its merger with Vyome Therapeutics [1][2][3] Group 1: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band System and investigational technologies for treating obesity and metabolic disorders [9] - Vyome Therapeutics focuses on developing a healthcare platform that leverages clinical-stage assets to address immune-inflammatory conditions, with plans for a reverse merger with ReShape Lifesciences [7] - Biorad Medisys Pvt. Ltd. is a growing med-tech company that specializes in precision-engineered medical devices across various segments, including urology and gastroenterology [8] Group 2: Proposals and Voting - The Asset Sale Proposal involves the sale of substantially all of ReShape's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, and is crucial for the merger [1][2] - The Charter Amendment Proposal seeks to amend ReShape's certificate of incorporation in connection with the merger, and its approval is also necessary for the operation of the combined company post-merger [3][4] - Stockholders are encouraged to vote in favor of both proposals, with the Special Meeting of Stockholders set to reconvene on August 7, 2025 [3][4]